Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SLAMF7 FPBMC
- Development stage
- Phase 2
- Lead developer
- University of Virginia
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
SLAMF7 FPBMC is an investigational cell therapy that combines fresh peripheral blood mononuclear cells (FPBMC) with a bispecific antibody targeting both CD3 and SLAM family member 7 (SLAMF7). The therapy is designed to enhance immune-mediated cytotoxicity against multiple myeloma cells by arming patient-derived immune cells with the bispecific antibody. The mechanism involves simultaneous engagement of T-cells (via CD3) and malignant plasma cells or NK cells (via SLAMF7), aiming to promote targeted killing of cancerous plasma cells in relapsed or refractory multiple myeloma. This approach leverages the immunostimulatory properties of SLAMF7, which is highly expressed on myeloma and certain immune effector cells[2][3][1].
- Other names
- SLAMF7 + FPBMCCS1 FPBMCCS-1 FPBMCCS 1 FPBMC
02
Targets
CD3 (T-cell surface glycoprotein CD3)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on SLAMF7 FPBMC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SLAMF7 FPBMC.